Canaccord Genuity Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $315
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a 'Hold' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $312 to $315.
August 07, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a 'Hold' rating on Vertex Pharmaceuticals and raises the price target from $312 to $315.
The news is directly about Vertex Pharmaceuticals. The 'Hold' rating suggests that the stock is expected to perform in line with the market or the sector in the next 12 months. The increase in price target indicates a slightly positive outlook but it's not significant enough to change the rating or the score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100